René Swanink

1.7k total citations
20 papers, 1.3k citations indexed

About

René Swanink is a scholar working on Psychiatry and Mental health, Genetics and Pharmacology. According to data from OpenAlex, René Swanink has authored 20 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 6 papers in Genetics and 5 papers in Pharmacology. Recurrent topics in René Swanink's work include Schizophrenia research and treatment (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Treatment of Major Depression (5 papers). René Swanink is often cited by papers focused on Schizophrenia research and treatment (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Treatment of Major Depression (5 papers). René Swanink collaborates with scholars based in United States, Belgium and Italy. René Swanink's co-authors include Ronald N. Marcus, William H. Carson, Robert D. McQuade, Robert Berman, Patricia K. Corey‐Lisle, Arif Khan, Christopher D. Breder, Taro Iwamoto, Maurizio Fava and Michael E. Thase and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

René Swanink

20 papers receiving 1.2k citations

Peers

Countries citing papers authored by René Swanink

Since Specialization

Citations

This map shows the geographic impact of René Swanink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by René Swanink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites René Swanink more than expected).

Fields of papers citing papers by René Swanink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by René Swanink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by René Swanink. The network helps show where René Swanink may publish in the future.

Co-authorship network of co-authors of René Swanink

This figure shows the co-authorship network connecting the top 25 collaborators of René Swanink. A scholar is included among the top collaborators of René Swanink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with René Swanink. René Swanink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Stephen M. Ansell, Paul J. Bröckelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro, Pier Luigi Zinzani, Graham P. Collins, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Mariano Provencio, Ulrich Jaeger, Wolfgang Willenbacher, René Swanink, Margaret A. Shipp, Andreas Engert, Philippe Armand	8
2	NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY 2021 ·Hematological Oncology ·Stephen M. Ansell, Paul J. Bröckelmann, Gottfried von Keudell, (unknown), Armando Santoro, Pier Luigi Zinzani, Graham P. Collins, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Mariano Provencio, Ulrich Jaeger, Wolfgang Willenbacher, René Swanink, Marco Sacchi, Margaret A. Shipp, Andreas Engert, Philippe Armand	12
3	Final results of CA180-372/COG AALL1122 phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly-diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (PH plus ALL) 2020 ·Stephen P. Hunger, Vaskar Saha, Meenakshi Devidas, M. Valsecchi, Julie M. Gastier‐Foster, Giovanni Cazzaniga, Shalini C. Reshmi, M Borowitz, Anthony V. Moorman, NA Heerema, Andrew J. Carroll, René Swanink, Peter Martin, Mignon L. Loh, Elizabeth A. Raetz, Konrad Schultz, William B. Slayton, Martin Schrappe, L. B. Silverman, Andrea Biondi	3
4	Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION 2020 ·Blood ·Massimo Breccia, Michael J. Mauro, Elias Jabbour, Giuseppe Saglio, Antonio Jiménez‐Velasco, Philipp D. le Coutre, (unknown), (unknown), Oumar Sy, René Swanink, Jörge E. Cortes	1
5	Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial 2018 ·Journal of Clinical Oncology ·Lia Gore, Pamela Kearns, (unknown), Lee ', Cármino Antônio De Souza, Yves Bertrand, Nobuko Hijiya, Linda C. Stork, Nack‐Gyun Chung, (unknown), Tapan Saikia, Franca Fagioli, Jong Jin Seo, Judith Landman‐Parker, Donna Lancaster, Andrew E. Place, Karen R. Rabin, Mariana Sacchi, René Swanink, C. Michel Zwaan	71
6	Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP). 2017 ·Journal of Clinical Oncology ·Lia Gore, Pamela Kearns, (unknown), Cármino Antônio De Souza, Yves Bertrand, Nobuko Hijiya, Linda C. Stork, Nack‐Gyun Chung, Rocío Cárdenas‐Cardós, Tapan Saikia, Franca Fagioli, (unknown), Judith Landman‐Parker, Donna Lancaster, Andrew E. Place, Karen R. Rabin, Mariana Sacchi, René Swanink, Michel Zwaan	1
7	Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study 2012 ·Annals of the Rheumatic Diseases ·Edward Keystone, Joel M. Kremer, Anthony S. Russell, J. Box, Carlos Abud‐Mendoza, Mario Alberto Garza‐Elizondo, Allison Luo, Richard Aranda, I. Delaet, René Swanink, Sheila Gujrathi, Michael E. Luggen	43
8	649 A Randomized Placebo-Controlled Trial of Abatacept for Moderately-to-Severely Active Crohn's Disease (CD) 2010 ·Gastroenterology ·Stephen B. Hanauer, William J. Sandborn, Bruce E. Sands, Paul Rutgeerts, Remo Panaccione, Brian Bressler, (unknown), René Swanink, Richard Aranda, Allison Luo	8
9	Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants 2009 ·CNS Spectrums ·Robert Berman, Maurizio Fava, Michael E. Thase, Madhukar H. Trivedi, René Swanink, Robert D. McQuade, William H. Carson, David E. Adson, Leslie Taylor, (unknown), Ronald N. Marcus	201
10	A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease 2008 ·American Journal of Geriatric Psychiatry ·Joel E. Streim, Anton P. Porsteinsson, Christopher D. Breder, René Swanink, Ronald N. Marcus, Robert D. McQuade, William H. Carson	83
11	Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder 2008 ·The Primary Care Companion to The Journal of Clinical Psychiatry ·Michael E. Thase, Madhukar H. Trivedi, J. Craig Nelson, Maurizio Fava, René Swanink, Quynh-Van Tran, (unknown), Huyuan Yang, Berit X. Carlson, Ronald N. Marcus, Robert Berman	34
12	A Double-Blind, Randomized Comparative Study of Aripiprazole and Olanzapine in Patients with Schizophrenia 2008 ·Biological Psychiatry ·W. Wolfgang Fleischhacker, Robert D. McQuade, Ronald N. Marcus, Donald Archibald, René Swanink, William H. Carson	85
13	Aripiprazole for the Treatment of Psychoses in Institutionalized Patients With Alzheimer Dementia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Assessment of Three Fixed Doses 2007 ·American Journal of Geriatric Psychiatry ·Jacobo Mintzer, Larry E. Tune, Christopher D. Breder, René Swanink, Ronald N. Marcus, Robert D. McQuade, Andrew Forbes	110
14	The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder 2007 ·The Journal of Clinical Psychiatry ·Robert Berman, Ronald N. Marcus, René Swanink, Robert D. McQuade, William H. Carson, Patricia K. Corey‐Lisle, Arif Khan	313
15	Effectiveness of aripiprazole v. Haloperidol in acute bipolar mania 2005 ·The British Journal of Psychiatry ·Eduard Vieta, Michel Bourin, Raymond Sanchez, Ronald N. Marcus, Elyse Stock, Robert D. McQuade, William H. Carson, (unknown), René Swanink, Taro Iwamoto	137
16	Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease 2005 ·Journal of Clinical Psychopharmacology ·Peter Paul De Deyn, Dilip V. Jeste, René Swanink, Dušan Kostić, Christopher D. Breder, William H. Carson, Taro Iwamoto	112
17	Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage^® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studies 2004 ·Diabetes Obesity and Metabolism ·Ken Fujioka, Ronald Brazg, Itamar Raz, Simon Bruce, Steven Joyal, René Swanink, Miranda Pans	56
18	P1-326 Dose-ranging study of aripiprazole in patients with dementia of Alzheimer's disease 2004 ·Neurobiology of Aging ·Christopher D. Breder, René Swanink, Ronald N. Marcus, Dušan Kostić, Taro Iwamoto, William H. Carson, Robert D. McQuade	3
19	P1-330 Flexible-dose aripiprazole in psychosis of Alzheimer's disease 2004 ·Neurobiology of Aging ·Joel E. Streim, Christopher D. Breder, René Swanink, Robert D. McQuade, Taro Iwamoto, William H. Carson, Elyse Stock	5
20	P.2.064 A dose-ranging study of aripiprazole treatment in patients with psychosis associated with Alzheimer's dementia 2004 ·European Neuropsychopharmacology ·(unknown), Christopher D. Breder, René Swanink, R. Marcus, (unknown), (unknown), Robert D. McQuade	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact